Zomedica (OTCMKTS:ZOMDF) and Abliva AB (publ) (OTCMKTS:NEVPF) Critical Analysis

Profitability

This table compares Zomedica and Abliva AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zomedica	-65.92%	-19.20%	-17.54%
Abliva AB (publ)	N/A	-117.92%	-102.44%

Institutional & Insider Ownership

9.0% of Zomedica shares are owned by institutional investors. 5.6% of Zomedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Zomedica and Abliva AB (publ)”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zomedica	$32.03 million	3.52	-$81.86 million	($0.02)	-5.75
Abliva AB (publ)	$10,000.00	1,128.43	-$9.01 million	N/A	N/A

Abliva AB (publ) has lower revenue, but higher earnings than Zomedica.

Risk & Volatility

Zomedica has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Abliva AB (publ) has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500.

Summary

Zomedica beats Abliva AB (publ) on 6 of the 9 factors compared between the two stocks.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

About Abliva AB (publ)

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.